Loading...
Loading...
FNCH| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 1.4M |
| Gross Profit | -1.3M |
| Operating Expense | 18.2M |
| Operating I/L | 29.8M |
| Other Income/Expense | -49.3M |
| Interest Income | 0.4M |
| Pretax | -67.4M |
| Income Tax Expense | -3.5M |
| Net Income/Loss | -63.9M |
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company focused on developing orally administered biological drugs. Its lead candidate, CP101, is in Phase 3 clinical trial for recurrent Clostridioides difficile infection and chronic hepatitis B virus. The company also develops FIN-211 for autism spectrum disorder, and TAK-524 and FIN-525 for ulcerative colitis and Crohn's disease. Finch generates revenue through the development and commercialization of these microbiome-based therapeutics, leveraging collaboration and license agreements with partners such as Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and University of Minnesota.
